Navigation Links
InteKrin Therapeutics to Present Phase 2b Clinical Data for Edema at the 2010 American Diabetes Association Annual Meeting

LOS ALTOS, Calif., June 18 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

Dr. Alex DePaoli, Acting Chief Medical Officer of InteKrin Therapeutics, will present "INT131 Besylate, a Selective PPAR-gamma Modulator (SPPARM), Improved Glycemic Control in Patients with Type 2 Diabetes without Causing the Edema Seen with Pioglitazone."

About INT131

INT131 is a next-generation insulin sensitizer that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of Type 2 Diabetes.  As a selective PPAR-gamma modulator (SPPARM), INT131 has been designed to provide potent glucose lowering and durability of effect without the recognized side effects of the currently available insulin sensitizers which, unlike INT131, are full PPAR-gamma agonists. InteKrin has completed an End-Of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for INT131 and is moving the program into Phase 3 development.

About InteKrin (

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin has assembled an experienced team of veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

To learn more about InteKrin, visit

SOURCE InteKrin Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
3. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
4. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
5. InteKrin Therapeutics Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their ... Award, an essay contest in which patients and their families pay tribute to a ... the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):